Vir Biotechnology (VIR) announced the completion of enrollment for ECLIPSE 1, a Phase 3 trial evaluating the safety and efficacy of the combination of tobevibart and elebsiran in patients with chronic hepatitis delta. ECLIPSE 1 is one of three trials in Vir Biotechnology’s ECLIPSE registrational program for CHD, and it is designed to provide the efficacy and safety data needed for potential submission to global regulatory agencies, including in the U.S. and Europe. Enrollment in the other two trials in the program, ECLIPSE 2 and ECLIPSE 3, is ongoing and on track. The last patient in ECLIPSE 1 is expected to reach the trial’s primary endpoint in the fourth quarter of 2026, with topline data expected in the first quarter of 2027.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VIR:
- Vir Biotechnology’s Innovative HDV Study: A Potential Game-Changer in Viral Treatment
- Vir Biotechnology’s Promising Phase 3 Study for Chronic HDV Treatment
- Vir Biotechnology’s Phase 3 Study on HDV Treatment: A Potential Game-Changer?
- Vir Biotechnology’s Innovative Approach in HER2-Expressing Cancer Treatment: A Study Update
- Vir Biotechnology’s Promising Prostate Cancer Study: A Potential Game-Changer?